Answers are grounded in this paper and cite their sources.
Observations indicate protein subunit RSV vaccine may benefit adults aged 60-74 years at risk for severe disease, suggesting vaccination could improve health outcomes.
Adults aged 60 to 74 years who are at increased risk for severe RSV may consider receiving a protein subunit RSV vaccine.
No takes yet. Share an insight, caveat, or question.
Qaseem et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: